FDA Recall: Baxter IV Cefazolin Bags With Cardboard Particulates—What to Do

FDA has posted a voluntary nationwide recall of one lot of Baxter IV cefazolin in dextrose (an antibiotic solution used to treat bacterial infections or prevent infection during surgery). The concern is cardboard-type particulate matter found in the bag/solution.

If you (or your family member) is receiving IV cefazolin in a hospital or clinic, this is usually handled as a “check-and-correct” situation by the facility. The practical takeaway: confirm the bag’s lot number and ask the bedside team/pharmacy what they are doing with the recalled lot.

Quick context: what happened and when

FDA says Baxter voluntarily recalled the product after a report of particulate matter in the solution identified as cardboard-type. FDA’s posting lists a company announcement date of July 24, 2026.

Exact product to look for (lot and expiration)

FDA identifies the affected product as:

Drug/Product: Cefazolin in Dextrose Injection, USP, 2 g / 100 mL (20 mg/mL), single-dose infusion bag
Manufacturer product code: 2G3508
Lot number: LD175708
Expiration date: 14-Feb-2027
NDC number: 0338-3508-41

FDA notes the affected lots can be identified by locating the lot number and expiration date printed on the package/carton and on the product labeling.

What FDA says the risk could be (in plain language)

FDA’s risk framing focuses on what could happen if foreign particles are infused intravenously. FDA states that the use of the defective product has a reasonable probability of serious complications such as:

Pulmonary emboli (blockage in the lungs’ blood vessels)
Occlusions of other blood vessels (which can lead to tissue injury and possible organ damage)
Phlebitis (inflammation of vein walls)

FDA also reports that Baxter had not received any reports of adverse events related to this issue as of the time of the FDA posting. (That doesn’t guarantee there will be no future reports.)

What you should do now (patients, families, caregivers)

Most people won’t need to do anything beyond confirming details with the clinical team. Use this step-by-step approach:

Ask the bedside team or pharmacy to confirm the lot number of the cefazolin bag being used.
Keep a record of what you’re told (lot number and expiration date), in case your facility needs it for documentation.
Ask what the facility’s recall process is for this product (for example, whether they are removing the affected lot from use and replacing it with another lot).
Tell your care team promptly if you notice symptoms that could suggest a blood clot or worsening IV-site inflammation.

Important: Don’t stop or change IV antibiotics on your own. In a hospital setting, medication selection and administration are handled by clinicians and pharmacists using the facility’s recall procedures.

What to watch for: symptoms that should trigger urgent evaluation

This recall’s concern is particulate matter entering the bloodstream. Because FDA mentions blood-vessel and vein-inflammation complications, use this symptom checklist as a “when to get help” guide.

Possible blood-clot symptoms (get urgent help / call for emergency assistance)

Shortness of breath or trouble breathing
Chest pain (especially if it worsens with breathing)
Coughing up blood
Swelling or pain in one leg (a possible warning sign of deep vein thrombosis)

Possible IV-site inflammation (notify the care team right away)

Increasing redness, warmth, swelling, or pain around the IV site
Tenderness along the vein near the IV
Hardness or worsening discomfort at the infusion site

For severe symptoms—especially breathing or chest symptoms—seek emergency care immediately.

Clinicians and pharmacy teams: what to review

For healthcare facilities, the action typically focuses on lot identification, reconciliation, and stopping use of affected inventory per the recall notice. A practical internal review includes:

Medication administration record review to verify whether any doses were connected to the recalled lot (matching lot number/expiration date).
Recall procedures for quarantining and replacing affected product so future administrations use unaffected lots.
IV-site monitoring for patients who received IV cefazolin during the time window when the recalled product could have been in use.

Why particulate matter in injectables is taken seriously

FDA has published guidance on visible particulates in injectable products and how they are handled in regulatory and quality contexts. The key theme: foreign/visible particles can be a safety issue because medication is intended to go to specific places in the body.

Clinical research has also explored relationships between infusion practices (such as filtration) and infusion-related vein inflammation (phlebitis). While general background like this can’t confirm what happened in this specific recall, it supports why clinicians monitor infusion sites and why facilities pay close attention to particulate contamination.

What remains uncertain

Lot-specific exposure: The recall applies to the identified lot. Not every patient receiving cefazolin is affected.
Outcome depends on clinical course and facility actions: Monitoring and next steps depend on whether any doses were administered and whether symptoms develop.
Reporting timing: FDA notes Baxter had not received reports of adverse events “to date” at the time of posting; later reports could occur.

Questions to ask your care team

“What is the lot number and expiration date of the cefazolin bag you’re using?”
“Is the facility removing lot LD175708 from use, and what product will replace it?”
“What symptoms should we watch for after receiving this medication?”
“If there’s any concern about the IV site, what’s the plan to evaluate or adjust the infusion?”

Key sources

Editorial note: Weence articles are researched from cited public-health, medical, regulatory, journal, and reputable news sources and may be drafted with AI assistance. They are checked for source support, clarity, and safety guardrails before publication.

This article is for general informational purposes only and is not medical advice. Research findings can be early or incomplete, and health guidance can change. Always talk with a qualified healthcare professional about personal symptoms, diagnosis, medications, vaccines, screenings, or treatment decisions. If you think you may have a medical emergency, call emergency services right away.